BDSI BEMA fentanyl NDA in Q2’07
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
BioDelivery Sciences plans to submit an NDA for its BEMA fentanyl oral adhesive disc in the second quarter of 2007, the company says Sept. 20. The Morrissville, N.C. firm is targeting use in breakthrough pain and projects $250 mil. in peak sales (1Pharmaceutical Approvals Monthly March 2006, p. 19). On Sept. 26, BDSI announced that the Research Advisory Panel of California approved the restart of two Phase III protocols of the proprietary fentanyl formulation. BDSI received a "not approvable" letter Feb. 28 for its antiemetic Emezine (prochlorperazine) for use in severe nausea and vomiting and subsequently began highlighting its BEMA formulations, which include a long-acting analgesic and zolpidem (Sanofi-Aventis' Ambien and tentatively approved generics)...
You may also be interested in...
BDSI Touts Pain Therapy Pipeline After Emezine "Not Approvable" Letter
BioDelivery Sciences International is touting the potential of its flagship analgesic pipeline and downplaying Emezine for severe nausea and vomiting after receiving a "not approvable" letter from FDA Feb. 28 for the latter treatment.
New China COVID Vaccine Arriving But COVAX Pledge May Need A Booster
China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.
QUOTED. 9 March 2021. Matthew Trerotola.
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: